Adkins DR, Haddad RI. Clinical trial data of anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal carcinoma: A review. Cancer Treat Rev 2022;109:102428. Abstract
Arbab M et al. Association between radiation dose to organs at risk and acute patient reported outcome duration radiation treatment for head and neck cancers. Head Neck 2022;44(6):1442-52. Abstract
Argiris A et al. Nivolumab (n) + ipilimumab (i) vs EXTREME regimen as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651. ESMO 2021;Abstract LBA36.
Belli C et al. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol 2021:32(3):337-50. Abstract
Besse B et al. Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: Updated from the registrational phase 2 TRIDENT-1 trial. AACR-NCI-EORTIC Virtual International Conference 2021;Abstract LB6546.
Brose MS et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(8):1126-38. Abstract
Chang ET et al. The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2021;30(6):1035-47. Abstract
Doebele RC et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21(2):271-82. Abstract
Drilon AE et al. Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer. ASCO 2022;Abstract 3100.
Florou V et al. Clinical activity of selitrectinib in a patient with mammary analogue secretory carcinoma of the parotid gland with secondary resistance to entrectinib. J Natl Compr Canc Netw 2021;19(5):478-82. Abstract
Gillison ML et al. Long-term outcomes with nivolumab as first-line treatment in recurrent or metastatic head and neck cancer: Subgroup analysis of CheckMate 141. Oncologist 2022;27(2):e194-8. Abstract
Haddad RI et al. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Canc 2022;10(2):e003026. Abstract
Hanna GJ et al. Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck. ASCO 2021;Abstract 6053.
Hong DS et al. Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020;21(4):531-40. Abstract
Hyman D et al. Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). AACR 2019;Abstract CT127.
Krzakowski MJ et al. Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors. ASCO 2022;Abstract 3099.
Larkin J. The medical oncologist point of view. ESMO 2022;Presidential Symposium II.
Le X et al. Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers. Oncologist 2022;[Online ahead of print]. Abstract
Machiels J-P et al. Primary results of the phase III KEYNOTE-412 study: Pembrolizumab plus chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). ESMO 2022;Abstract LBA5.
Mai H-Q et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: A multicenter randomized phase 3 trial. Nat Med 2021;27(9):1536-43. Abstract
Mansfield AS et al. Pralsetinib in patients (pts) with advanced ore metastatic RET-altered thyroid cancer (tc): Updated data from the ARROW trial. ASCO 2022;Abstract 6080.
Mody MD et al. Head and neck cancer. Lancet 2021;398(10318):2289-99. Abstract
Schoenfeld JD et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: A phase 2 open-label randomized clinical trial. JAMA Oncol 2020;6(10):1563-70. Abstract
Shah H et al. Use of fluoro-[18F]-deoxy-2-D-glucose positron emission tomography/computed tomography to predict immunotherapy treatment response in patients with squamous cell oral cavity cancers. JAMA Otolaryngol Head Neck Surg 2022;148(3):268-76. Abstract
Subbiah V et al. Pralsetinib for patients with advanced ore metastatic RET-altered thyroid cancer (ARROW): A multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol 2021;9(8):491-501. Abstract
Tahara M et al. Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma: 5-year results from KEYNOTE-048. ESMO 2022;Abstract 659MO.
Uppaluri R et al. Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). ASCO 2021;Abstract 6008.
Uppaluri R et al. Correction: Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: A multicenter, phase II trial. Clin Cancer Res 2021;27(1):357. Abstract
Wirth LJ et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020;383(9):825-35. Abstract
Xu RH et al. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus cisplatin and gemcitabine as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). ASCO 2021;Abstract LBA2.
Yang Y et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2021;22(8):1162-74. Abstract
Zhang L. RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer. ASCO 2022;Abstract 384950.